ArticleThe journal of obstetrics and gynaecology research2025
Real-world clinical outcomes of patients with high-risk endometrial cancer or endometrial carcinosarcoma in England: A retrospective cohort study.
Article in The journal of obstetrics and gynaecology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world clinical outcomes of patients with high-risk endometrial cancer or endometrial carcinosarcoma in England: A retrospective cohort study.The journal of obstetrics and gynaecology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimThe objectives of this study were to describe patient characteristics and estimate real-world disease-free survival (rwDFS) and overall survival (OS) from initiation of first adjuvant therapy among patients with high-risk endometrial cancer (EC) in England.
methodsThis was a retrospective cohort study based on data from Public Health England's National Cancer Registration and Analysis Service (NCRAS) between 2014 and 2023. Adult women with EC or endometrial carcinosarcoma at high risk of recurrence who received adjuvant therapy within 90 days after surgery were eligible for inclusion. We operationalized rwDFS as time to next treatment or death.
resultsIn total, 6036 women (mean age: 67 years; 86% White) were eligible for inclusion, with a mean follow-up of 48 months. During the study period, 45% of patients experienced recurrence and 39% of patients died due to any cause. Median rwDFS and OS from initiation of adjuvant therapy were estimated at 4.56 years (95% CI: 4.14-5.12) and 8.85 years (95% CI: 8.15-9.82), respectively. Estimated 2-year and 5-year probabilities were 0.64 (95% CI: 0.63-0.65) and 0.49 (95% CI: 0.48-0.50) for rwDFS, and 0.78 (95% CI: 0.77-0.79) and 0.60 (95% CI: 0.58-0.61) for OS, respectively. Disease recurrence was associated with a 3.23-fold higher risk of death (p < 0.001). Kendall's τ correlation coefficient between rwDFS and OS was 0.75 (95% CI: 0.69-0.80, p < 0.001).
conclusionsThe results from our study underscore the substantial clinical burden and unmet medical need of women with high-risk EC and the validity of rwDFS as a surrogate for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.